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Abstract. Oligonucleotide therapeutics hold great promise for the treatment of various diseases and the antisense field is
constantly gaining interest due to the development of more potent and nuclease resistant chemistries. Despite a rather low
success rate with only three antisense drugs being clinically approved, the frontiers of AON therapeutic applications have
increased over the past three decades and continue to expand thanks to a steady increase in understanding the mechanisms
of action of these molecules, progress in chemical modification and delivery.
In this review, we will examine the recent advances obtained with the tricyclo-DNA chemistry which displays unique phar-
macological properties and unprecedented uptake in many tissues after systemic administration. We will review their specific
properties and their therapeutic applications mainly for neuromuscular disorders, including exon-skipping for Duchenne
muscular dystrophy and exon-inclusion for spinal muscular atrophy, but also aberrant splicing correction for Pompe disease.
Finally, we will discuss their advantages and potential limitations, with a focus on the need for careful toxicological screen
early in the process of AON drug development.
Keywords: Antisense oligonucleotides, splicing correction, exon-skipping, exon-reinclusion, nanoparticles, delivery
INTRODUCTION
The development of the antisense oligonucleotide
(AON)-based approach started with the work of
Zamecnik and Stephenson in 1978 when oligonu-
cleotides were used as tools to downregulate the
expression of specific genes [1]. The earliest strate-
gies aimed to modulate gene expression through
inhibition of protein translation via steric hindrance
of translation initiation sites within the 5′ untranslated
region of the targeted gene. AONs were origi-
nally unmodified synthetic DNA complementary
∗Correspondence to: Luis Garcia, U1179 UVSQ-INSERM
Biothe´rapies des Maladies du Syste`me Neuromusculaire UFR
des sciences de la sante´ Simone Veil, Universite´ de Versailles
saint Quentin, 2 Avenue de la source de la bie`vre, 78180 Mon-
tigny le bretonneux, France. Tel.: +33 1 70 42 94 16; E-mail:
luis.garcia@uvsq.fr.
to the targeted mRNA but it rapidly became evi-
dent that chemical modifications to protect AONs
from nuclease degradation were necessary. Since
the natural phosphodiester internucleotide linkage is
highly sensitive to nucleases, it was the obvious site
for chemical modification. Various backbones have
been introduced over the years but it is interesting
to note that the very first one, the phosphoroth-
iate (PS) linkage is still the most widely used
backbone modification in therapeutic AONs. The
other prime site for chemical modification is the
2′-position in the sugar moiety and it has been
widely used in the antisense field. This includes
modifications such as 2′-O-methyl (2′OMe), 2′-O-
methoxyethyl (2′O-MOE), 2′-fluorinated (2′F) and
2′-O-aminopropyl analogs. Incorporation of these
2′-modified sugars considerably increases binding
affinity and pharmacokinetics of AONs over their
2′-deoxy counterparts. Similar characteristics are
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Fig. 1. Chemical structures of a selection of oligonucleotide analogues that have been tested as antisense agents (2′OMe: 2′OMethyl, 2′MOE:
2′OMethoxyethyl, LNA: Locked nucleic acid, PMO: Phosphorodiamidate morpholino oligomer, PNA: Peptide nucleic acid, bc-DNA:
Bicyclo-DNA, tc-DNA: Tricyclo-DNA).
found in oligonucleotides with backbones based on
Phosphorodiamidate morpholino oligomer (PMO),
peptide nucleic acid (PNA), locked nucleic acid
(LNA), phosphoramidate and methyl-phophonate
derivatives (Fig. 1). These advances in the develop-
ment of antisense chemistries have led to numerous
studies investigating the therapeutic potential of anti-
sense technology and clinical applications (for review
see [2]). AONs offer therapeutic options in several
ways, including the classical targeted gene knock-
down, achieved through the recruitment of RNAse H1
to degrade mRNA at sites of DNA/RNA hybridization
upon AON binding. For this purpose however, most
AONs containing chemical modifications need to be
designed as “gapmers” with a DNA core (or “gap”)
to induce RNAse H activity flanked by nuclease
resistant-modified ends to improve drug stability and
tissue distribution. Fully modified AONs on the other
hand can be used for other applications which have
rapidly gained attention over the last two decades,
amongst others the antisense mediated elimination
of mRNA toxicity or the manipulation of alternative
splicing where the antisense molecules are also called
splice switching oligonucleotides (SSO). In this con-
text, oligonucleotides can be used to modulate the
ratio of splicing variants or correct splicing defects,
by inducing exon-skipping or exon-inclusion, which
opened far reaching implications in the treatment
of a variety of diseases. The field has progressed
very quickly over the last few years and promising
results have been achieved, leading to several clinical
evaluations.
Notably, most of these advances have been
made for neuromuscular disorders (NMDs) such as
Duchenne muscular dystrophy (DMD) using exon-
skipping, Spinal muscular atrophy (SMA) using exon
re-inclusion or aberrant splicing correction for pompe
disease. In this review, we focus on the recent
pre-clinical developments using the tricyclo-DNA
chemistry which displays unique pharmacological
properties and unprecedented uptake in many tissues
after systemic administration. We will examine their
therapeutic potential in the context of NMDs such as
DMD, SMA and the Pompe disease and discuss the
promises and challenges of this chemistry.
PHYSICOCHEMICAL PROPERTIES
OF TC-DNA
Tricyclo-(tc)-DNA has been designed in the late
nineties as a conformationally constrained DNA
analogue (Fig. 1) [3, 4]. It is thus a second gener-
ation analogue of bicyclo-(bc)-DNA which has been
introduced as the first member of the class of con-
formationally constrained DNA analogues in 1993
[5]. The basic concept behind conformational restric-
tion consists in reducing the torsional flexibility of
the sugar phosphate backbone within the repeating
nucleotide units, thereby structurally preorganizing
the single strand for duplex formation. This reduces
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the entropy of duplex formation and leads thus to
more stable duplexes.
Fully modified tc-DNA containing all four natural
nucleobases reveal increases in thermal stability of
duplexes with complementary DNA by ca 1.2◦C/mod
and with complementary RNA of ca 2.4◦C/mod [6].
The fidelity of Watson-Crick base-pair formation is
slightly increased as compared to natural DNA. As
expected the driving force for the increased thermo-
dynamic stability of duplexes is a more favourable
entropy term as determined from Tm vs concentra-
tion variation experiments. Tc-DNA residues show
the highest stabilization if used as fully modi-
fied oligonucleotides. Single tc-DNA units do not
mix very well with the DNA backbone and even
less with the RNA backbone, due to energetic
penalties arising from structural dissimilarities at
the backbone junction sites [7]. However, tc-DNA
can efficiently be used as gapmers as we will
see below.
Structurally, tc-DNA is rather an RNA than a
DNA-analogue as it prefers an overall A-like duplex
conformation with complementary DNA and RNA.
This has been demonstrated by molecular modelling
and by CD-spectroscopy and could very recently be
confirmed by a high resolution NMR structure of
a fully modified tc-DNA/RNA duplex (unpublished
data).
Fully modified tc-DNA in its phosphate form is
highly stable against nuclease activity in murine and
human serum and does not elicit RNaseH activity
[8]. The latter fact can easily be explained by the
preference of tc-DNA for an RNA like structure. Even
tc-DNA gapmers with 5 nucleotide tc-DNA wings
and a core of 8 natural DNA nucleotides in the center
of the sequence are still highly stable in human serum.
As expected, such gapmers are RNaseH competent
due to the natural DNA window [9].
As common for the 2′-O-alkyl-RNAs or LNAs, tc-
DNA can also be prepared with a phosphorothioate
backbone (tc-PS-DNA). Besides negative effects like
the occurrence of diastereomeric mixtures of oligonu-
cleotides within the same sequence scheme, there are
also general advantages such as a significant increase
in nuclease stability and cellular uptake and trans-
port. In contrast to most other phosphodiester based
oligonucleotide chemistries tc-DNA is already highly
nuclease stable in its phosphate form [8, 9]. Hence,
there is no need to use tc-PS-DNA just for increas-
ing nuclease resistance. However, it turns out that
tc-PS-DNA shows increased plasma transport, cellu-
lar uptake and tissue distribution over normal tc-DNA
which makes it the candidate of choice for therapeutic
applications [10].
Over the years the potential for antisense applica-
tions of tc-DNA either in the phosphate (tc-DNA) or
thiophosphate (tc-PS-DNA) form has been evaluated
in various systems and formats. Outside therapeutic
applications of tc-PS-DNA in the field of neuro-
muscular disorders, which is outlined in more detail
below, tc-DNA has been used for splice correction in
a cellular assay with HeLa cells stably expressing the
human -globin gene containing two different muta-
tions in intron 2. These mutations activate a cryptic
splice site, leading to the inclusion of an aberrant
exon. In a comparative study with a tc-DNA 17-mer,
masking the cryptic splice site, it appeared that tc-
DNA was able to restore correct splicing by a factor
of up to 100-fold more efficiently compared to 2′-
OMe-PS-RNA [8]. In another set of experiments fully
modified tc-DNA has been directed to the cyclophilin
A gene in order to induce exon skipping. Again, in
a comparative cellular assay, it was shown that a tc-
DNA 11-mer showed significant exon skipping while
fully modified LNA of the same length was virtually
inactive [11]. In another comparative assay, tc-DNA
was tested for its capacity to act as a steric blocker
AON of human immunodeficiency virus type 1 tat-
dependent trans-activation as a means to inhibit HIV
viral replication. Here it was found that a fully mod-
ified tc-AON showed the same inhibitory activity as
an LNA/2′OMe-RNA mixmer of the same length.
Corresponding tc-DNA/2′OMe-RNA mixmers were
significantly less active demonstrating again that tc-
DNA does not mix well with 2′O-Me-RNA (see also
above) [12]. In a final benchmark experiment tc-
PS-DNA gapmers of lengths between 14 and 20 nt
were tested for their capability to downregulate scav-
enger receptor B1 mRNA in mice. It turned out that
the tc-DNA gapmers outperformed corresponding 2′-
MOE-RNA gapmers in activity not only in the liver
but also in other non-hepatic tissues such as kidney,
heart, lung, diaphragm and skeletal muscles [10].
THERAPEUTIC POTENTIAL FOR NMDS
Exon skipping therapy for DMD
As mentioned above, fully modified AONs are
particularly useful to manipulate alternative splicing
and splice modulation therapy, where the antisense
molecules, also called SSOs can be used to correct
splicing defects either by inducing exon-skipping,
exon-reinclusion or masking aberrant splice splices,
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Fig. 2. Antisense oligonucleotides mediated splice correction for various neuromuscular diseases. A - Exon skipping rationale for DMD.
Patients with DMD carry mutations disrupting the open-reading frame of the dystrophin pre-mRNA. In this example, exon 50 is deleted,
creating an out-of-frame mRNA and leading to the synthesis of a truncated non-functional or unstable dystrophin. The tc-DNA AON directed
against exon 51 can induce effective skipping of exon 51 and restore the open reading frame, therefore generating an internally deleted but
partly functional dystrophin. B – Exon inclusion rationale for SMA. Exon 7 of SMN2 gene is spliced out in 90% of the mature mRNA
leading to only 10% of functional SMN protein. Tc-DNA AON can mask the ISS inducing inclusion of exon 7 and leading to a functional
SMN protein.
is a promising therapy for numerous genetic diseases.
One of the most studied examples till date is for DMD
where the AONs aim at skipping one or several exons
to restore the reading frame (Fig. 2A).
DMD is a lethal X-linked progressive muscle-
wasting disease caused by mutations, typically large
deletions in the DMD gene, the largest gene in
the human genome [13]. Most mutations, including
deletions (approximately 65%), duplications, point
mutations or other small gene rearrangements disrupt
the open reading frame, leading to aberrant transla-
tion and, therefore, to the absence of the essential
muscle protein dystrophin. Interestingly, the allelic
disease Becker muscular dystrophy (BMD), which
results in a much milder phenotype, is mainly caused
by mutations maintaining the open reading frame
and allowing the production of a partially deleted
but functional dystrophin [14]. Antisense-mediated
exon-skipping strategies for DMD aim to remove the
mutated exon alone or together with additional exons
to restore the reading frame and consequently induce
the expression of “BMD-like” shortened forms of
dystrophin retaining crucial functions. Although the
exon-skipping approach appears to be applicable to
a large proportion of patients (possibly up to approx-
imately 83% of all DMD patients [15]), one should
keep in mind that this will not offer a definite cure
but an improvement towards a BMD-like phenotype
depending on the functionality of the restored dys-
trophin.
The principle of the exon-skipping therapy for
DMD has first been demonstrated by Pramono et al.
in 1996 in lymphoblastoid cells and by Dunckley
et al. in 1998 in cultured mouse cells in vitro [16, 17].
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Since then, numerous in vivo studies have provided
pre-clinical evidence for the therapeutic potential
of an antisense strategy for DMD in several ani-
mal models. In particular, the mdx mouse model,
which harbors a nonsense mutation in exon 23, has
been used extensively to test efficacy of the AON
approach using various oligonucleotide chemistries
such as 2′OMe [18], phosphorodiamidate morpholino
oligomers (PMO) [19–21], LNA or PNA [22, 23].
Recently, we have demonstrated the therapeutic
potential of tc-DNA in this mouse model follow-
ing systemic treatment for 12 weeks [24]. The
tc-DNA-AON was stable and detected in all tested
skeletal muscles as well as the heart and brain after
intravenous injections. Quantitative PCR revealed
effective skipping of exon 23 to levels 5-6-fold higher
than that achieved with 2′OMe and PMO AONs,
which are the two chemistries currently in trial for
DMD. Importantly, this translated into a greater res-
cue of dystrophin protein levels, particularly in the
diaphragm and heart, where levels reached 50%
and 40% respectively, compared to wild-type mice.
Notably, exon 23 skipping and dystrophin protein
expression were seen in the central nervous system
(CNS) of only those animals treated with tc-DNA-
AON.
Restoration of dystrophin expression significantly
improved the mdx mouse phenotype. The specific
force of tibialis anterior muscles was essentially
normalized and maintained up to 80% following
eccentric contractions (used to measure the structural
integrity of muscle fibres). A significant improvement
in respiratory function was also noted, to a greater
extent than that seen with 2′OMe or PMO AON treat-
ment. In addition, echocardiography revealed that
the tc-DNA-AON significantly improved ventricular
ejection fraction and shortening fraction. For the first
time, we could also demonstrate that tc-DNA-AON
also had beneficial effects in the CNS. Tonic immo-
bility (freezing) resulting from a restraint-induced
fear response - a highly reproducible behavioral phe-
notype of mdx mice that is controlled by central
mechanisms – was the same in tc-DNA-AON-treated
mdx and WT mice, whereas the responses of the
2′OMe- and PMO AON-treated mdx mice did not
differ from untreated mdx mice. Intravenous tc-DNA-
AON treatment for 20 weeks was similarly effective
in a more severe mouse model of DMD, lacking
both utrophin and dystrophin (dko mouse model).
It partially rescued dystrophin protein expression in
all affected tissues, leading to significant phenotypic
improvements.
This study demonstrated for the first time some of
the unique properties of the tc-DNA-AON such as
their ability to efficiently target the cardiac muscle,
but also their capacity to cross the blood brain barrier
and restore certain behavioural aspects linked to the
absence of dystrophin in the CNS.
Using DMD mouse models, we were able to eval-
uate a broad biodistribution across all tissues and
calculated a half life of the tc-DNA AONs of approx-
imately 45 days in skeletal muscles. The long lasting
activity of tc-DNA lead to satisfactory levels of dys-
trophin upon regimens using lower doses designed to
balance a possible toxicity due to chronic exposure
to high levels of AONs. When such an approach was
carried out in mdx mice (4 weeks at 200 mg/kg/wk
followed by 8 weeks at 50 mg/kg/wk), high levels
of exon skipping and dystrophin restoration were
detected and were comparable to that found in mice
treated at 200 mg/kg over 12 weeks [24]. Interest-
ingly, when comparing low dose treatment regimen
of AONs in mdx mice, we were able to detect signif-
icant levels of exon skipping in mice treated with as
low as 20 mg/kg of tc-DNA whereas similar dosing
regimen using 2′OMe or PMO AONs hardly induced
any detectable exon skipping (unpublished data).
It is well accepted in the field that AON uptake
is facilitated in dystrophic muscles and an enhanced
absorption of AON from the blood circulation of up
to 8 fold as compared to wild type muscles was pre-
viously reported for 2′OMe for example [25]. This
is believed to be caused by the myogenic degener-
ation and regeneration processes in the mdx mice,
associated with a higher permeability of the myofiber
membranes and/or vascular system. Interestingly, we
found that tc-DNA biodistribution in wild type mice
was not so different and levels of exon skipping
detected after 4 intravenous injections were only 50%
of the levels detected in mdx mice (unpublished data).
Exon inclusion strategy for spinal muscular
atrophy (SMA)
As well as modulating splicing to remove exons
from the mature transcript, tc-DNA can be used to
promote exon-inclusion and a typical example of this
strategy is considered as one of the most promising
therapeutic approach for SMA. SMA is caused by
mutations in the SMN1 (Survival Motor Neuron 1)
gene. The SMN locus presents a telomeric copy of
SMN1 which encodes the SMN protein, and cen-
tromeric copies of SMN2 which produce very few
SMN. SMN2 differs from SMN1 by only a C to T
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transition in the coding sequence of exon 7 (not affect-
ing the protein sequence), which however results in
exclusion of exon 7 in about 90% of mature tran-
scripts [26, 27]. Therefore SMN2 gene expression
leads only to approximately 10% of functional SMN
protein and the copy number of SMN2 thus corre-
lates with the severity of the disease. As an example,
severe forms (type I) carry 2 copies while type III
SMA patients carry three or four SMN2 copies. Exon
7 inclusion has been shown as a promising therapeutic
strategy for SMA by using AONs (Fig. 2B) and in par-
ticular 2′O-MethoxyEthyl (2′MOE) and PMO AONs.
However, despite advances in antisense oligonu-
cleotides chemistry and design, the delivery of AONs
to the central nervous system remains a challenge, and
intracerebroventricular (ICV) injections are required
in mice to induce exon 7 inclusion in brain [28, 29],
although best pre-clinical results in mice were gener-
ally obtained when ICV injections were coupled with
IP injection, confirming the peripheral role of SMN
[30]. This is where the unique properties of tc-DNA,
being able to cross the blood brain barrier become
particularly interesting allowing us to evaluate the
contribution of central and peripheral restoration of
SMN following systemic delivery. Tc-DNA AONs
annealing to the TSL (terminal stem loop) or the
downstream ISS (intronic splicing silencer) improv-
ing the strength of the 5′donor splice site were shown
to restore SMN expression and activity in SMA cells
(Robin et al.; manuscript in preparation). Further-
more, subcutaneous treatment of SMA type III mice
with a 15mer tc-DNA targeting the downstream ISS
sequence induced an efficient exon 7 inclusion in all
tissues including the CNS, leading to an improve-
ment in type III SMA mice phenotype, by preventing
tail, ear and toe necrosis. This type III SMA mouse
model, which is considered mild compared to the
severe type I mouse model, survives and breeds nor-
mally [31], allowing a later start of treatment (7
days of age for example with tc-DNA) compared
to day 1 for the severe model. Detection of exon
7 inclusion in brain and spinal cord following tc-
DNA subcutaneous treatment starting at 7 days of age
therefore confirmed the specific properties of tc-DNA
AONs and their ability to cross the blood brain bar-
rier at least at low levels (Robin et al.; manuscript in
preparation).
Aberrant splicing correction for pompe disease
Another mutation affecting normal splicing of
mRNA is found in the GAA gene encoding the acid
alpha-glucosidase enzyme (GAA), causing Pompe
disease or glycogenosis type II (GSD-II), an inherited
recessive metabolic myopathy (incidence: 1/40,000).
Hundreds of GAA mutations have been identified, but
few of them are more common, particularly the [c.-32
-13T>G] mutation [32, 33], which is found in >40%
of alleles in adult Caucasian patients and 90% of
patients included in the French database [34]. Most
severe splice mutations (e.g. totally disabling the
splicing reactions) are those that typically affect the
consensus donor (GU) or acceptor (AG) splice sites at
the 5′ and 3′ ends of introns, thus impairing transester-
ification reactions. Mutations which affect cis-acting
regulatory elements (silencers or enhancers) and
other RNA features influencing splicing are usually
less severe given that resulting inhibition is often
incomplete and some normal transcripts can still be
synthesised. The T to G transition provoked by the
[c.-32-13T>G] mutation in the GAA gene is one of
those, which strongly decreases but not completely
abolish the normal inclusion of the second exon into
the GAA mRNA during the maturation of the nascent
pre-mRNA transcript. The consequence of such mis-
splicing is that ensuing 2-GAA mRNAs (more
than 90% of the GAA transcripts resulting from the
mutated gene) lack their start codon and thus cannot
be translated into a protein [35]. The [c.–32-13T>G]
mutation is located at the 3′ end of the intron 1, within
the polypyrimidine (Py) tract, among the branch site
(in humans the branch consensus is yUnAy) and the
AG splice site, which allows the recruitment of the
dimeric U2 auxiliary factor protein or U2AF, identi-
fied as a major site of splicing regulation. Therefore,
a common explanation for the effect of the [c.-32 -
13T>G] mutation is that the T to G transition weakens
the strength of the Py tract, which could not any more
efficiently recruit U2AF [36]. Nonetheless, the fact
that the Py consensus varies somewhat in length and
sequence for every intron does not support such an
assumption. Instead, the T>G transition might alter
the correct removal of intron 1 by modifying the sec-
ondary structure of the pre-mRNA at the level of its 3′
acceptor splice site, thus making it ineffective. This
is supported by the analysis of the intron-1/exon-
2 boundary with the RNAfold software from the
ViennaRNA Web Services, which shows major dif-
ferences for the predicted secondary structures in
normal and mutated sequences. In both cases, MFE
(minimum free energy) predicted structures show
that this particular region of the pre-mRNA could
likely form a hairpin, although such a structure is
dramatically reinforced in the mutant (Fig. 3A). As
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Fig. 3. A - ESE finder and MFE (minimal free energy) secondary structure predictions: Notice that the beginning of exon-2 is markedly
deprived of ESE (exon splice enhancer) sites binding SRSF (Serine/arginine splicing factors) but shows ESS (exon splice silencer) sites for
hnRNP A1 (boxed – yellow contributes to the 5′ UTR; light purple designates coding sequence). The T>G transition might alter the correct
removal of intron-1 by modifying the secondary structure of the pre-mRNA at the level of its 3′ acceptor splice site (e.g. generating a locked
hairpin), thus making it ineffective. B - Splice switching rationale to rescue the [c.-32-13 T>G] common mutation: MFE analysis of the
region spanning the end of intron-1 and the beginning of exon-2 in the presence of a 15-mer tcDNA-AON annealing exon-2 at position [+7 to
+22]. The frequency of the new MFE structure is 25% instead of 65%. (SA1: Acceptor splice site 1, U2AF: U2 auxilliary factor, U2snRNP:
U2 small nuclear ribonucleoprotein).
a result, the high base-pairing probability of the
nucleotides involved in the secondary structure of the
mutant pre-mRNA makes almost inaccessible some
of the crucial consensus sequences at the 3′ end of
intron-1, such as the acceptor splice site (SA1), the
pyrimidine tract for U2AF recruitment and the branch
site. To summarize, it appears that the T>G transi-
tion might alter the correct removal of intron-1 by
adding force to a cryptic hairpin self-annihilating
SA1.
According to these assumptions, one can pro-
pose a method for rescuing a full length GAA
mRNA in patient cells with the [c.-32 -13T>G] muta-
tion by using antisense oligonucleotides designed to
anneal the 5′ region of exon-2 involved in the puta-
tive hairpin described above, hence allowing to set
free SA1 and its key upstream cis-elements (Py &
branch site) without masking downstream ESE sites
(Fig. 3B). Such a rationale has been established ex
vivo on skin fibroblasts derived from a compound
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heterozygote patient harbouring the [c.–32 -13T>G]
mutation, by using tc-DNA-AONs targeting the puta-
tive hairpin and therefore rescuing the expression of a
functional protein (Avril et al;, manuscript in prepara-
tion). Considering the very properties of the tc-DNA
oligonucleotides, which are efficiently distributed
into all skeletal muscles, in particular respiratory
muscles, the heart and the CNS, one could anticipate
that a splice-switching strategy might likely provide
a suitable treatment option for patients with late-
onset Pompe disease for whom current treatments are
quite ineffective. Interestingly, a recent study using
the antisense technology, but targeting the muscle
specific glycogen synthase, and not the GAA gene
directly, demonstrated encouraging results and could
also represent a viable therapeutic strategy for Pompe
disease after further development [37].
Speciﬁc properties/advantages of tc-DNA
Through these various applications, it appears
that the tc-DNA chemistry may represent a new
avenue for the synthesis of novel splice-switching
drugs for many neuromuscular disorders. The very
mechanisms responsible for the enhanced activity of
tc-DNA are not yet fully understood. We have previ-
ously described using nanoparticle tracking analysis
(NTA), Size-Exclusion Chromatography with Multi-
Angle Static Light Scattering (SEC-MALS) and
dynamic light scattering (DLS) that in contrast to the
corresponding 2′OMe and PMO oligomers, tc-DNA
AONs spontaneously form defined nanoparticles
ranging from 40–100 nm [24, 38]. This propensity
to spontaneously self-assemble into nanoparticles
could imitates features of transfection reagents and
nanoparticle delivery systems [39] and hence could
potentially improve cellular uptake compared to
2′OMe and PMO oligomers. While it is not known
whether self-assembly of tc-DNA is maintained in
vivo and therefore responsible for increased potency,
we have demonstrated that this process is maintained
in physiological conditions and in the presence of
serum proteins [38]. The involvement of class A
scavenger receptors (SCARAs) together with other
polyI sensitive scavenger receptors (SR) has also
been shown in gymnosis conditions in vitro [38]. It
is feasible to speculate that the superior activity of
tc-DNA is related to its propensity to self-assemble
into nanoparticles mediating better SR interaction
and subsequent gymnotic uptake, which would fit
with the particle-wrapping model for receptor medi-
ated uptake of nanoparticles [39, 40]. The mechanism
of spontaneous tc-DNA self-assembly is not well
understood. The three additional C atoms increase the
hydrophobicity of the molecule and this might impart
secondary amphipathic properties on the structure
enabling self-assembly via mechanisms resembling
the self assembly of ampipathic peptides [41]. Alter-
natively, the extra rings in the tc-DNA might facilitate
stacking and generation of structures resembling
poly-G aggregates that were seen to enhance the
uptake of AONs and binding to SR [42].
We could also hypothesize that tc-DNA as
nanoparticles or free AONs might bind naturally to
appropriate, not yet identified, carriers in the blood-
stream allowing them to cross endothelial barriers
more efficiently. Structural and modeling studies are
underway to unravel the mechanism of tc-DNA self
assembly and their protein binding profile.
A further crucial feature of the tc-DNA chemistry
is that it displays higher RNA binding properties
than 2′OMe and PMO [43], thus permitting use of
AONs of decreased length. Importantly, this offers
the advantage of reducing the mass of synthetic
nucleotides administered while keeping biological
effect, which could reduce toxicity induced by accu-
mulation of AONs. In a recent study, we compared
the effect and therapeutic potential of a 15-nt and
a 13-nt tc-DNA in the mdx mouse model (Relizani
et al., manuscript in preparation) and demonstrated
that systemic delivery of 13nt-tcDNA allows restora-
tion of dystrophin in skeletal muscles at similar levels
to a 15nt. Remarkably in the heart, the 13nt-tcDNA
induces significantly higher levels of exon skipping
and dystrophin restoration than its 15nt counterpart,
suggesting a potential size advantage for uptake in
the cardiac muscle. However, these unique uptake
properties are not entirely due to the small size of tc-
DNA since treatment with a 20nt tc-DNA also leads
to efficient uptake in the cardiac muscle (unpublished
data).
While using small size AONs offers an advan-
tage in terms of cost of production, decreasing the
sequence length makes it increasingly more chal-
lenging to identify a unique target site. Furthermore,
increased binding energy has the capacity to not
only increase potency against the intended target but
also to “off-targets” and the so-called hybridization-
mediated off-targets effects (OTEs) may become a
more prevalent concern. However because splicing
modulation is highly dependent on target sequence
position in the intended RNA target, effects on unin-
tended off-target RNAs containing perfect match are
extremely unlikely with splice switching AONs as
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opposed to gapmers AONs recruiting RNAse H [44,
45]. OTEs have not been noted with great abundance
in preclinical or clinical studies to date, probably
because not all off-target binding actually leads to
functional effects. Not all sites on mRNA are accessi-
ble to an ASO, nor are all off-target mRNAs in tissues
that receive pharmacologic concentrations of an ASO
as they are differentially and temporally expressed in
different tissues.
One of the unique opportunities of AONs-based
therapeutics is that putative off-target interactions can
be predicted using sequence alignment algorithms
and pragmatic genomic screening strategies are in
place in most companies developing AON-based
drugs to delineate potential OTEs. The Oligonu-
cleotide safety Working group (OSWG) recommends
assessment of OTEs for AONs during drug discovery
and development, both computationally and experi-
mentally [46] and such studies are currently on-going
for tc-DNA.
While these recommendations and screening are
necessary, OTEs are generally not the main concern in
the antisense field. Instead, the toxicities noted have
been overwhelmingly associated with those expected
by class. Each class of AON from first to third gen-
eration has stereotypic toxicity profiles and these
nuances are important for the toxicologic patholo-
gist to be aware of [44]. We have recently evaluated
the toxicological profile of tc-DNA AONs in DMD
mouse model and shown that high dose tc-DNA
treatment (200 mg/kg/wk for 12 weeks) was well-
tolerated in all mice. Histopathological findings in
tc-DNA-treated animals were generally limited to
minimal glomerular changes and few cell necrosis
in proximal tubules (Relizani et al., manuscript in
preparation). Serum biochemistry analysis following
12 weeks of treatment did not reveal any signifi-
cant increase in transaminases or bilirubin, and only
a slight variation in serum creatinine and urinary
kidney toxicity biomarkers levels could be detected,
which is typical of the PS-AONs accumulation in kid-
neys. Similarly, no toxic effects were observed at any
dosage using SMA mouse models during the course
of our experiments (with respect to clinical obser-
vations, organ weights, macroscopic observations
at necropsy). These results suggest an encouraging
safety profile for tc-DNA although one should remain
cautious until full toxicological studies are completed
since we cannot exclude a possible acute toxicity
which would be sequence specific as it has previously
been reported with the LNAs, inducing unexpected,
sequence specific hepatotoxicity [47].
CONCLUSION
Within the last few years the prospect of successful
AON-based splicing therapy for neuromuscular dis-
orders has moved a step closer, particularly for DMD
and SMA. Many of these promising therapies have
now entered clinical trials and encouraging results
have been obtained in most cases, while also show-
ing the limitations of currently used chemistries. The
large number of planned and on-going trials using the
antisense technology reflects the optimism of these
approaches to regulate gene expression and modulate
splicing. Much of this optimism can be attributed to
the development of novel oligonucleotides modifica-
tions, such as the tc-DNA described in this review
or the use of cell penetrating peptide which also
demonstrated extremely promising results. Recent
preclinical work in animal models using these new
classes of AONs, which improve tissue uptake, tar-
get binding affinity as well as resistance to nuclease
degradation, suggest that solutions to the current chal-
lenges of systemic and tissue targeted delivery are
close at hand. While we focused this review on DMD,
SMA and Pompe disease, it should be noted that
many other NMDs could benefit from the progresses
described here and several preclinical studies have
actually demonstrated the therapeutic potential of
AONs in other pathologies as reviewed extensively by
Van Roon-Mom and Aartsma-Rus [48] and Disterer
and colleagues [49].
The very properties of tc-DNA described in this
review make them particularly attractive as AONs
drugs for such genetic diseases, and clinical evalua-
tion of tc-DNA for the treatment of DMD is currently
being planned. However, the promise of tc-DNA still
crucially depends on how well it will be tolerated in
humans.
With continued success, we will hopefully see a
gradual implementation of novel modifications which
will improve potency of these drugs over the coming
years and that will increasingly extend lifespan and
improve the quality of life for patients with neuro-
muscular diseases.
ACKNOWLEDGMENTS
The authors have financial support from the
Agence nationale de la recherche (ANR – Chair
of Excellence HandiMedEx), the Association Mon-
egasque contre les myopathies (AMM) and the
Duchenne Parent project France (DPPF).
Journal Identification = JND Article Identification = 160146 Date: May 27, 2016 Time: 2:12 pm
166 A. Goyenvalle et al. / Therapeutic Potential of Tc-DNA AONs
COMPETING FINANCIAL INTERESTS
Christian Leumann and Luis Garcia are co-
funders of Synthena, which produces tricyclo-DNA
oligomers.
REFERENCES
[1] Zamecnik PC, Stephenson ML. Inhibition of Rous sar-
coma virus replication and cell transformation by a
specific oligodeoxynucleotide. Proc Natl Acad Sci U S A.
1978;75(1):280-4. Epub 2015/08/19.
[2] McClorey G, Wood MJ. An overview of the clinical appli-
cation of antisense oligonucleotides for RNA-targeting
therapies. Curr Opin Pharmacol. 2015;24:52-8.
[3] Steffens R, Leumann CJ. Synthesis and Thermodynamic
and Biophysical Properties of Tricyclo-DNA. J Am Chem
Soc. 1999;121(14):3249-55.
[4] Steffens R, Leumann CJ. Tricyclo-DNA: A phosphodiester-
backbone based DNA analog exhibiting strong com-
plementary base-pairing properties. J Am Chem Soc.
1997;119(47):11548-9.
[5] Tarko¨y M, Leumann C. Synthesis and Pairing Properties of
Decanucleotides from (3′S,5′R)-2′-Deoxy-3′, 5′-ethano-
D-ribofuranosyladenine and -thymine. Angew Chem Int Ed.
1993;32(10):1432-4.
[6] Renneberg D, Leumann CJ. Watson-Crick base-pairing
properties of tricyclo-DNA. J Am Chem Soc. 2002;
124:5993-6002.
[7] Ittig D, Gerber AB, Leumann CJ. Position-dependent
effects on stability in tricyclo-DNA modified oligonu-
cleotide duplexes. Nucleic Acids Res. 2011;39(1):373-80.
[8] Renneberg D, Schu¨mperli D, Leumann CJ. Biological and
antisense properties of tricyclo-DNA. Nucleic Acids Res.
2002;30:2751-7.
[9] Ittig D, Renneberg D, Vonlanthen D, Luisier S, Leumann
CJ. Oligonucleotide analogues: From supramolecular prin-
ciples to biological properties. In: Hocec M, editor. XIII
Symposium on the chemistry of nucleic acid components;
Spindleruv. Institute of Organic Chemistry and Biochem-
istry, Academy of Sciences of the Czech Republic, Prague:
Collection Symposium Series. 2005;21-6.
[10] Murray S, Ittig D, Koller E, Berdeja A, Chappell
A, Prakash TP, et al. TricycloDNA-modified oligo-2′-
deoxyribonucleotides reduce scavenger receptor B1 mRNA
in hepatic and extra-hepatic tissues—a comparative study of
oligonucleotide length, design and chemistry. Nucleic Acids
Res. 2012;40(13):6135-43.
[11] Ittig D, Liu S, Renneberg D, Schu¨mperli D, Leumann CJ.
Nuclear antisense effects in cyclophilin A pre-mRNA splic-
ing by oligonucleotides: A comparison of tricyclo-DNA
with LNA. Nucleic Acids Res. 2004;32:346-53.
[12] Ivanova G, Reigadas S, Ittig D, Arzumanov A, Andreola
ML, Leumann C, et al. Tricyclo-DNA Containing Oligonu-
cleotides as Steric Block Inhibitors of HIV-1 Tat-Dependent
Trans Activation and HIV-1 Infectivity. Oligonucleotides.
2007;17(1):54-65.
[13] Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations:
One gene, several proteins, multiple phenotypes. Lancet
Neurol. 2003;2(12):731-40.
[14] Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H,
Kunkel LM. An explanation for the phenotypic differences
between patients bearing partial deletions of the DMD locus.
Genomics. 1988;2(1):90-5.
[15] Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van
Deutekom J, van Ommen GJ, et al. Theoretic applica-
bility of antisense-mediated exon skipping for Duchenne
muscular dystrophy mutations. Hum Mutat. 2009;30(3):
293-9.
[16] Pramono ZA, Takeshima Y, Alimsardjono H, Ishii A,
Takeda S, Matsuo M. Induction of exon skipping of the
dystrophin transcript in lymphoblastoid cells by transfect-
ing an antisense oligodeoxynucleotide complementary to
an exon recognition sequence. Biochem Biophys Res Com-
mun. 1996;226(2):445-9. Epub 1996/09/13.
[17] Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson
G. Modification of splicing in the dystrophin gene in cul-
tured Mdx muscle cells by antisense oligoribonucleotides.
Hum Mol Genet. 1998;7(7):1083-90.
[18] Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue
SA, et al. Functional amounts of dystrophin produced by
skipping the mutated exon in the mdx dystrophic mouse.
Nat Med. 2003;9(8):1009-14.
[19] Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen
RD, Wilton SD. Dystrophin expression in the mdx mouse
after localised and systemic administration of a mor-
pholino antisense oligonucleotide. J Gene Med. 2006;8(2):
207-16.
[20] Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen
RD, Steinhaus JP, et al. Morpholino oligomer-mediated
exon skipping averts the onset of dystrophic pathology in
the mdx mouse. Mol Ther. 2007;15(9):1587-92.
[21] Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter
J, et al. Systemic delivery of antisense oligoribonucleotide
restores dystrophin expression in body-wide skeletal mus-
cles. Proc Natl Acad Sci U S A. 2005;102(1):198-203.
[22] Ivanova GD, Arzumanov A, Abes R, Yin H, Wood MJ,
Lebleu B, et al. Improved cell-penetrating peptide-PNA
conjugates for splicing redirection in HeLa cells and
exon skipping in mdx mouse muscle. Nucleic Acids Res.
2008;36(20):6418-28.
[23] Yin H, Lu Q, Wood M. Effective exon skipping and
restoration of dystrophin expression by peptide nucleic
acid antisense oligonucleotides in mdx mice. Mol Ther.
2008;16(1):38-45.
[24] Goyenvalle A, Griffith G, Babbs A, Andaloussi SE, Ezzat
K, Avril A, et al. Functional correction in mouse models
of muscular dystrophy using exon-skipping tricyclo-DNA
oligomers. Nat Med. 2015. Epub 2015/02/03.
[25] Heemskerk H, de Winter C, van Kuik P, Heuvelmans
N, Sabatelli P, Rimessi P, et al. Preclinical PK and PD
studies on 2′-O-methyl-phosphorothioate RNA antisense
oligonucleotides in the mdx mouse model. Mol Ther.
2010;18(6):1210-7. Epub 2010/04/22.
[26] Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single
nucleotide in the SMN gene regulates splicing and is respon-
sible for spinal muscular atrophy. Proc Natl Acad Sci U S
A. 1999;96(11):6307-11. Epub 1999/05/26.
[27] Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy
EJ, Burghes AH, et al. A single nucleotide difference
that alters splicing patterns distinguishes the SMA gene
SMN1 from the copy gene SMN2. Hum Mol Genet.
1999;8(7):1177-83. Epub 1999/06/17.
[28] Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, Bennett
CF, et al. Antisense correction of SMN2 splicing in the CNS
rescues necrosis in a type III SMA mouse model. Genes Dev.
2010;24(15):1634-44.
Journal Identification = JND Article Identification = 160146 Date: May 27, 2016 Time: 2:12 pm
A. Goyenvalle et al. / Therapeutic Potential of Tc-DNA AONs 167
[29] Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF,
et al. Peripheral SMN restoration is essential for long-term
rescue of a severe spinal muscular atrophy mouse model.
Nature. 2011;478(7367):123-6. Epub 2011/10/08.
[30] Osman EY, Miller MR, Robbins KL, Lombardi AM,
Atkinson AK, Brehm AJ, et al. Morpholino antisense
oligonucleotides targeting intronic repressor Element1
improve phenotype in SMA mouse models. Hum Mol
Genet. 2014;23(18):4832-45.
[31] Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, Tsai
CH, et al. A mouse model for spinal muscular atrophy. Nat
Genet. 2000;24(1):66-70.
[32] Kroos MA, Pomponio RJ, Hagemans ML, Keulemans JL,
Phipps M, DeRiso M, et al. Broad spectrum of Pompe dis-
ease in patients with the same c.-32-13T->G haplotype.
Neurology. 2007;68(2):110-5. Epub 2007/01/11.
[33] Zampieri S, Buratti E, Dominissini S, Montalvo AL, Pittis
MG, Bembi B, et al. Splicing mutations in glycogen-storage
disease type II: Evaluation of the full spectrum of mutations
and their relation to patients’ phenotypes. Eur J Hum Genet.
2011;19(4):422-31. Epub 2010/12/24.
[34] Laforet P, Laloui K, Granger B, Hamroun D, Taouagh N,
Hogrel JY, et al. The French Pompe registry. Baseline char-
acteristics of a cohort of 126 patients with adult Pompe
disease. Revue neurologique. 2013;169(8-9):595-602. Epub
2013/09/07.
[35] Raben N, Nichols RC, Martiniuk F, Plotz PH. A model
of mRNA splicing in adult lysosomal storage disease
(glycogenosis type II). Hum Mol Genet. 1996;5(7):995-
1000. Epub 1996/07/01.
[36] Dardis A, Zanin I, Zampieri S, Stuani C, Pianta A,
Romanello M, et al. Functional characterization of the
common c.-32-13T>G mutation of GAA gene: Identifica-
tion of potential therapeutic agents. Nucleic Acids Res.
2014;42(2):1291-302. Epub 2013/10/24.
[37] Clayton NP, Nelson CA, Weeden T, Taylor KM, Moreland
RJ, Scheule RK, et al., Antisense Oligonucleotide-mediated
Suppression of Muscle Glycogen Synthase 1 Synthesis as
an Approach for Substrate Reduction Therapy of Pompe
Disease. Mol Ther Nucleic Acids. 2014;3:e206. Epub
2014/10/29.
[38] Ezzat K, Aoki Y, Koo T, McClorey G, Benner L, Coenen-
Stass A, et al. Self-Assembly into Nanoparticles Is Essential
for Receptor Mediated Uptake of Therapeutic Antisense
Oligonucleotides. Nano letters. 2015;15(7):4364-73. Epub
2015/06/05.
[39] Nel AE, Madler L, Velegol D, Xia T, Hoek EM,
Somasundaran P, et al. Understanding biophysicochem-
ical interactions at the nano-bio interface. Nat Mater.
2009;8(7):543-57. Epub 2009/06/16.
[40] Gao H, Shi W, Freund LB. Mechanics of receptor-mediated
endocytosis. Proc Natl Acad Sci U S A. 2005;102(27):9469-
74. Epub 2005/06/24.
[41] Pujals S, Fernandez-Carneado J, Lopez-Iglesias C, Kogan
MJ, Giralt E. Mechanistic aspects of CPP-mediated
intracellular drug delivery: Relevance of CPP self-
assembly. Biochim Biophys Acta. 2006;1758(3):264-79.
Epub 2006/03/21.
[42] Wu CC, Castro JE, Motta M, Cottam HB, Kyburz D,
Kipps TJ, et al. Selection of oligonucleotide aptamers with
enhanced uptake and activation of human leukemia B cells.
Hum Gene Ther. 2003;14(9):849-60. Epub 2003/06/28.
[43] Renneberg D, Bouliong E, Reber U, Schumperli D, Leu-
mann CJ. Antisense properties of tricyclo-DNA. Nucleic
Acids Res. 2002;30(13):2751-7. Epub 2002/06/28.
[44] Frazier KS. Antisense oligonucleotide therapies: The
promise and the challenges from a toxicologic patholo-
gist’s perspective. Toxicol Pathol. 2015;43(1):78-89. Epub
2014/11/12.
[45] Kamola PJ, Kitson JD, Turner G, Maratou K, Eriksson S,
Panjwani A, et al. In silico and in vitro evaluation of exonic
and intronic off-target effects form a critical element of
therapeutic ASO gapmer optimization. Nucleic Acids Res.
2015;43(18):8638-50. Epub 2015/09/05.
[46] Lindow M, Vornlocher HP, Riley D, Kornbrust DJ, Burchard
J, Whiteley LO, et al. Assessing unintended hybridization-
induced biological effects of oligonucleotides. Nat Biotech-
nol. 2012;30(10):920-3. Epub 2012/10/12.
[47] Swayze EE, Siwkowski AM, Wancewicz EV, Migawa MT,
Wyrzykiewicz TK, Hung G, et al. Antisense oligonu-
cleotides containing locked nucleic acid improve potency
but cause significant hepatotoxicity in animals. Nucleic
Acids Res. 2007;35(2):687-700. Epub 2006/12/22.
[48] van Roon-Mom WM, Aartsma-Rus A. Overview on appli-
cations of antisense-mediated exon skipping. Methods Mol
Biol. 2012;867:79-96. Epub 2012/03/29.
[49] Disterer P, Kryczka A, Liu Y, Badi YE, Wong JJ, Owen
JS, et al. Development of therapeutic splice-switching
oligonucleotides. Hum Gene Ther. 2014;25(7):587-98.
Epub 2014/05/16.
